Trial of PACEBOM versus CHOP in histologically aggressive non-Hodgkins lymphoma

ISRCTN	ISRCTN24219839
DOI	https://doi.org/10.1186/ISRCTN24219839
Protocol serial number	LY3
Sponsor	Cancer Research UK (CRUK) (UK)
Funders	Cancer Research UK, Lymphoma Research Trust, Lisa Lear Fund, Isle of Man Anti-Cancer Association

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Lymphoma (non-Hodgkins)
Intervention	Patients were randomised to one of two regimens: 1. CHOP Regimen: Multi-drug chemotherapy with cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP) repeated every 28 days. A minimum of six courses to be given with two courses beyond the attainment of complete response 2. PACEBOM Regimen: Multi-drug chemotherapy with prednisolone, adriamycin, cyclophosphamide and etoposide (PACE) alternating every 7 days with bleomycin, vincristine and methotrexate (BOM). Six cycles of PACE and five of BOM to be given
Intervention type	Other
Primary outcome measure(s)	Not provided at time of registration
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	31/10/1992

Participant type(s)	Patient
Age group	Not Specified
Sex
Key inclusion criteria	1. Aged 16 to 69 years 2. Previously untreated histologically aggressive lymphoma with a large cell component: Diffuse large cell, Diffuse immunoblastic, Diffuse mixed cell 3. Stages II-IV 4. No contraindications to treatment protocols
Key exclusion criteria	Patients with Burkitt's and lymphoblastic lymphoma to be excluded
Date of first enrolment	01/11/1987
Date of final enrolment	31/10/1992

UKCCCR Register Co-ordinator

London
NW1 2DA
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/1996		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes